Literature DB >> 25944677

Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.

Raphaele Renard-Penna1, Geraldine Cancel-Tassin, Eva Comperat, Morgan Roupret, Pierre Mozer, Olivier Cussenot.   

Abstract

INTRODUCTION: According to recent reports from randomized studies comparing radical treatment or watchful waiting, the outcome of localized prostate cancer remains uncertain at individual level. It is especially true for the low-risk group (according D'Amico or CAPRA classifications), regarding the individual exposition to overtreatment by radical therapies or the opposite risk of under-treatment with active surveillance.
MATERIAL AND METHODS: In this review, we describe the available molecular predictor tests and functional MRI, as well as their potential role in the selection of the appropriate treatment for prostate cancer patients.
CONCLUSION: The recent development of functional MRI imaging and clinical practice approval of molecular predictor tests for the assessment of the aggressive prostate cancer have brought new perspectives for the management of localized prostate cancer by active surveillance, focal ablative therapy or radical therapies.

Entities:  

Mesh:

Year:  2015        PMID: 25944677     DOI: 10.1007/s00345-015-1570-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  58 in total

1.  Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?

Authors:  Yasushi Itou; Katsuyuki Nakanishi; Yoshifumi Narumi; Yasuko Nishizawa; Hideaki Tsukuma
Journal:  J Magn Reson Imaging       Date:  2011-01       Impact factor: 4.813

2.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

3.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

Review 4.  Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.

Authors:  Linda A Bradley; Glenn E Palomaki; Steven Gutman; David Samson; Naomi Aronson
Journal:  J Urol       Date:  2013-03-29       Impact factor: 7.450

5.  Correlation of magnetic resonance imaging tumor volume with histopathology.

Authors:  Baris Turkbey; Haresh Mani; Omer Aras; Ardeshir R Rastinehad; Vijay Shah; Marcelino Bernardo; Thomas Pohida; Dagane Daar; Compton Benjamin; Yolanda L McKinney; W Marston Linehan; Bradford J Wood; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

6.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

7.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Authors:  R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

8.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

9.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Authors:  J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

10.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Authors:  Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal:  BMC Med       Date:  2008-07-08       Impact factor: 8.775

View more
  1 in total

1.  Management of low- and intermediate-risk prostate cancer.

Authors:  Henk van der Poel; Laurence Klotz; Christian G Stief
Journal:  World J Urol       Date:  2015-07       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.